NOVO:TSX, Novo Nordisk CDR (CAD Hedged)
NOVO stock overview
Novo Nordisk CDR (CAD Hedged) (NOVO:TSX) closed at $18.38 on November 13, 2026,
up 4.14% on the day.
The stock trades 33.4% below its 52-week high of $27.58
and 23.5% above its 52-week low of $14.88.
Over the past year, it lost 9.6%.
Novo Nordisk CDR (CAD Hedged) is part of the Health Care sector.
Key figures
- Price
- $18.38
- Day change
- +4.14%
- Volume
- 22,120
- Average volume
- 12,936
- Market cap
- 81B+
- 52-week range
- $14.88 – $27.58
- 50-day average
- $17.38
- 200-day average
- $18.36
Price action over the past year
In 246 trading sessions since November 21, 2025, NOVO closed higher on 118 days (48%).
Its best day was January 16, 2026 (+13.69%) and its worst was February 23, 2026 (-16.11%).
The stock moved 10% or more in a single session 4 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
NOVO news
-
Nov 13, 2026:
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
-
Nov 13, 2026:
Novo Nordisk Submits Sickle Cell Disease Treatment Etavopivat for US and European Regulatory Approval
-
Nov 13, 2026:
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?
-
Nov 13, 2026:
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
-
Nov 13, 2026:
Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways
-
Nov 13, 2026:
Novo Nordisk (CPSE:NOVO B) Taps DJ Khaled As Oral Weight Loss Race Heats Up
-
Nov 13, 2026:
Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill
-
Nov 13, 2026:
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
About Novo Nordisk CDR (CAD Hedged)
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Similar stocks
Find more stocks like NOVO with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.